Recent Posts

• Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis
• Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting
• Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
• Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis